David Sinclair· PhD
It's not continuous mTOR suppression that drives healthspan benefits—it's the oscillation between suppression and recovery that appears to activate cellular maintenance pathways.
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
It's not continuous mTOR suppression that drives healthspan benefits—it's the oscillation between suppression and recovery that appears to activate cellular maintenance pathways.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
It's not continuous mTOR suppression that drives healthspan benefits—it's the oscillation between suppression and recovery that appears to activate cellular maintenance pathways.
So the animal data have suggested and the human data have suggested that an intermittent dosing of rapamycin could produce a beneficial phenotype with respect to longevity specifically and also with respect to immune function.
so i would start off with that episodically like they did because i think there's some evidence that that you're getting just as big a boost without the side effects without the side effects
I think rapy does have significant longevity benefits in basically all models that aren't humans so the extrapolation would be pulsatile rapamycin is probably beneficial but it's in that application it's not really being taken to constantly suppress mtor
rapamycin is not really i mean it's never really been a particularly successful cancer therapeutic it used constitutively which is how it would be used obviously i'm i think rapamycin does have significant longevity benefits in basically all models that aren't humans so the extrapolation would be pulsatile rapamycin is probably beneficial
I think Rapa does have significant longevity benefits in basically all models that aren't humans so the extrapolation would be pulsatile rapamycin is probably beneficial but it's in in that application it's not really being taken to constantly suppress mtor because remember if you took it all the time you're suppressing mtor complex 2 and mtor complex one
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.